AEterna Zentaris and AVI BioPharma Maintain Steady Pipelines
The Bedford Report Provides Equity Research on AEterna Zentaris & AVI BioPharma
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 09/06/11 -- The importance of maintaining a steady pipeline of drugs to market is having varied effects on the biotechnology industry. Analysis by the professional services firm BDO argues that larger Pharmaceutical firms are increasing reliance on biotech companies to fill its pipeline, which has been a net positive for small biotech companies. The Bedford Report examines the outlook for companies in the biotechnology industry and provides investment research on AEterna Zentaris, Inc. (NASDAQ: AEZS) (TSX: AEZ) and AVI BioPharma, Inc. (NASDAQ: AVII). Access to the full company reports can be found at:
While the positive fundamentals are there, last month biotech stocks suffered from what MarketWatch's Val Brickates Kennedy calls the "Dendreon Effect." The article reports that biotech companies whose stocks have taken heavy hits include those that are at early stages of marketing new treatments.
"Pretty much every company that had just launched a product or was about to launch a product got crushed," Leerink Swann analyst Howard Liang explains.
The Bedford Report releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.
Aeterna Zentaris is a late-stage oncology drug development company currently investigating potential treatments for various cancers including colorectal, multiple myeloma, endometrial, ovarian, prostate and bladder cancer. Recently the company reported positive late-stage results for its product used to diagnose adult growth hormone deficiency.
AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. For the second quarter of 2011 AVI reported an operating loss of $10.1 million compared with an operating loss of $7.7 million in the second quarter of 2010.
The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at .
Contact:
The Bedford Report
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 06.09.2011 - 12:16 Uhr
Sprache: Deutsch
News-ID 62429
Anzahl Zeichen: 0
contact information:
Town:
NEW YORK, NY
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 257 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AEterna Zentaris and AVI BioPharma Maintain Steady Pipelines"
steht unter der journalistisch-redaktionellen Verantwortung von
The Bedford Report (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
